tiprankstipranks
In this article:
Blurbs

H.C. Wainwright Thinks TG Therapeutics’ Stock is Going to Recover

In this article:
In this article:

In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on TG Therapeutics (TGTXResearch Report), with a price target of $19.00. The company’s shares closed last Thursday at $5.04, close to its 52-week low of $4.73.

According to TipRanks.com, White is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -30.8% and a 18.4% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics.

Currently, the analyst consensus on TG Therapeutics is a Moderate Buy with an average price target of $14.71.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $41.00 and a one-year low of $4.73. Currently, TG Therapeutics has an average volume of 2.57M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.

Read More on TGTX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed